Company profile for Agendia

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Agendia is the only molecular diagnostics company focused solely on breast cancer. With our groundbreaking genomic testing, we generate reliable and meaningful clinical data about the unique biology of a woman’s breast cancer. Backed by prestigious physicians and institutions globally, we are shifting the standard of care towards more ideal, personalized treatment.We believe in the power of genomic testing to better inform t...
Agendia is the only molecular diagnostics company focused solely on breast cancer. With our groundbreaking genomic testing, we generate reliable and meaningful clinical data about the unique biology of a woman’s breast cancer. Backed by prestigious physicians and institutions globally, we are shifting the standard of care towards more ideal, personalized treatment.We believe in the power of genomic testing to better inform the patient journey – from the moment of diagnosis to remission, and beyond. It sheds light on complex treatment decisions, leading to the most relevant and targeted approach for each individual patient.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
22 Morgan, Irvine, CA 92618
Telephone
Telephone
(888) 321-2732
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Cosmoprof

Cosmoprof

Not Confirmed

envelop Contact Supplier

Cosmoprof

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20260120068346/en/Agendia-Announces-NCCN-Guideline-Update-Recognizing-MammaPrint-to-Guide-Personalized-Anthracycline-Use-in-HRHER2--EarlyStage-Breast-Cancer

BUSINESSWIRE
20 Jan 2026

https://www.businesswire.com/news/home/20251125677896/en/Agendia-to-Showcase-MammaPrint-and-BluePrint-Utility-in-Guiding-Anthracycline-Therapy-at-the-2025-San-Antonio-Breast-Cancer-Symposium

BUSINESSWIRE
25 Nov 2025

https://www.businesswire.com/news/home/20250812214330/en/Agendia-Announces-Publication-in-JNCI-Cancer-Spectrum-Demonstrating-that-MammaPrint-Predicts-Chemotherapy-Benefit-in-HRHER2--Early-Breast-Cancer-Using-Real-World-Evidence-from-the-FLEX-Study

BUSINESSWIRE
12 Aug 2025

https://www.businesswire.com/news/home/20250527845347/en/Agendia-to-Reveal-Novel-Breast-Cancer-Outcome-Data-Identifying-Genomic-Risk-and-Treatment-Disparities-Among-Diverse-Patient-Population-at-2025-ASCO-Annual-Meeting

BUSINESSWIRE
27 May 2025

https://www.businesswire.com/news/home/20250515469869/en/Agendia-to-Unveil-Novel-Data-on-Genomic-Risk-and-Treatment-Disparities-in-Early-Stage-Breast-Cancer-at-2025-ASCO-Annual-Meeting

BUSINESSWIRE
15 May 2025

https://www.globenewswire.com/news-release/2025/05/08/3077424/0/en/Agendia-Named-2025-Best-Overall-Genomics-Company-By-MedTech-Breakthrough.html

GLOBENEWSWIRE
08 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty